China Pharma Holdings, Inc.
CPHI Healthcare Drug Manufacturers Specialty & Generic
China Pharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, down 8.49% from fiscal 2024. In the quarter to June 2026, revenue fell 7.56%, EPS grew 75.0%, free cash flow fell 113.6% and total debt fell 2.92%, each against the same quarter a year earlier.
Follow CPHI
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
3.75 | 2.78 | 2.48 | 1.23 | 1.01 | 4.95 | 2.04 | 1.49 | 0.65 | 0.35 |
Receivables |
4.22 | 2.46 | 1.09 | 0.68 | 0.53 | 0.74 | 0.45 | 0.66 | 0.26 | 0.29 |
Inventory |
7.31 | 6.41 | 5.06 | 3.59 | 3.71 | 3.34 | 2.95 | 3.73 | 2.27 | 1.62 |
Other current assets |
2.00 | 0.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.44 | 0.00 | 0.02 | 0.01 |
Total current assets |
17.52 | 12.29 | 8.75 | 5.58 | 5.32 | 9.09 | 5.96 | 6.00 | 3.27 | 2.35 |
Property, Plant, Equpment (Net) |
24.97 | 23.54 | 19.29 | 16.31 | 15.56 | 13.28 | 9.97 | 7.10 | 4.88 | 4.39 |
Advances, Deposits, Owenrship interests |
35.50 | 23.72 | 17.07 | — | — | — | — | — | — | — |
Goodwill and Intangible Assets (Total) |
0.53 | 0.40 | 0.27 | 0.21 | 0.18 | 0.15 | 1.81 | 3.26 | 6.70 | 24.08 |
Total non-current assets |
61.00 | 47.66 | 36.63 | 16.66 | 15.80 | 13.56 | 11.82 | 10.47 | 11.62 | 28.65 |
Total Assets |
78.52 | 59.95 | 45.38 | 22.24 | 21.12 | 22.65 | 17.78 | 16.47 | 14.89 | 31.00 |
Notes Payable |
1.09 | 0.71 | 1.27 | 0.11 | — | — | 3.80 | 0.94 | — | — |
Accounts Payable |
3.06 | 1.14 | 1.06 | 1.37 | 1.23 | 0.93 | 0.67 | 0.97 | 0.23 | 0.89 |
Accrued Expenses |
0.14 | 0.28 | 0.31 | 0.19 | 0.18 | 0.30 | 0.40 | 0.30 | 0.25 | 0.35 |
Current Part of Debt |
1.44 | 2.31 | 2.18 | 2.15 | 4.34 | 4.33 | 2.44 | 1.03 | 1.02 | 1.98 |
Other current liabilities |
0.81 | 0.58 | 0.53 | 0.51 | 0.72 | 0.21 | 0.52 | 0.09 | 0.16 | 0.11 |
Total current liabilities |
10.40 | 9.23 | 10.05 | 10.05 | 11.40 | 10.51 | 12.74 | 6.82 | 5.02 | 7.40 |
Long Term Debt (Total) |
8.64 | 6.92 | 4.36 | 2.15 | 0.90 | 5.25 | — | 1.41 | 1.39 | — |
Long Term Tax Liability (Deferred) |
0.57 | 0.74 | 0.76 | 0.75 | 0.81 | 0.82 | 0.75 | 0.74 | 0.73 | 0.75 |
Total non-current liabilities |
9.21 | 7.65 | 5.13 | 2.95 | 1.71 | 6.12 | 0.75 | 2.19 | 2.12 | 0.86 |
Total liabilities |
19.61 | 16.88 | 15.18 | 13.00 | 13.11 | 16.63 | 13.49 | 9.01 | 7.14 | 8.26 |
Additional Paid In Capital |
23.59 | 23.59 | 23.59 | 23.59 | 24.45 | 25.65 | 28.93 | 35.28 | 40.63 | 58.54 |
Common Stock (Net) |
0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.00 | 0.01 | 0.00 | 0.02 |
Retained Earnings |
24.76 | 5.48 | (5.27) | (25.97) | (28.84) | (32.24) | (36.21) | (39.29) | (44.03) | (47.21) |
Shareholders Equity (Other) |
— | — | — | — | — | — | — | — | (0.18) | (0.18) |
Common Equity (Total) |
58.91 | 43.07 | 30.20 | 9.24 | 8.00 | 6.02 | 4.29 | 7.45 | 7.75 | 22.74 |
Shareholders Equity (Total) |
58.91 | 43.07 | 30.20 | 9.24 | 8.00 | 6.02 | 4.29 | 7.45 | 7.75 | 22.74 |
Shareholders Equity and Liabilities (Total) |
78.52 | 59.95 | 45.38 | 22.24 | 21.12 | 22.65 | 17.78 | 16.47 | 14.89 | 31.00 |
Shares (Common) |
0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.15 | 1.06 | 3.26 | 15.52 |
Shareholders Equity (Tangible) |
58.37 | 42.67 | 29.93 | 9.03 | 7.82 | 5.87 | 2.48 | 4.20 | 1.05 | (1.34) |
Net Debt |
6.33 | 6.44 | 4.06 | 3.07 | 4.23 | 4.63 | 0.40 | 0.95 | 1.76 | 1.63 |
Total Debt |
10.08 | 9.22 | 6.54 | 4.30 | 5.24 | 9.58 | 2.44 | 2.44 | 2.41 | 1.98 |